正川股份：10月24日召开董事会会议

Group 1 - The core point of the article is that Zhengchuan Co., Ltd. announced the convening of its fifth board meeting to review the third quarter report for 2025 [1] - For the year 2024, the revenue composition of Zhengchuan Co., Ltd. indicates that the pharmaceutical manufacturing sector accounts for 99.58% of total revenue, while other businesses contribute 0.42% [1] - As of the report, Zhengchuan Co., Ltd. has a market capitalization of 3 billion yuan [1] Group 2 - The article highlights that Chinese innovative drugs have generated $80 billion in overseas licensing deals this year [1] - It features an interview with Lu Gang, a partner at Chuangdong Investment, discussing the hot secondary market in biomedicine and the cooling fundraising environment in the primary market [1]